VPH Stock Overview A specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Valeo Pharma Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Valeo Pharma Historical stock prices Current Share Price CA$0.045 52 Week High CA$0.39 52 Week Low CA$0.04 Beta 2.3 1 Month Change 0% 3 Month Change -35.71% 1 Year Change -67.86% 3 Year Change -94.08% 5 Year Change -83.93% Change since IPO -93.08%
Recent News & Updates
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Sep 14
Price target decreased by 20% to CA$0.40 Sep 13
Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024 Sep 09
Valeo Pharma Inc. Announces Board Changes Aug 07
Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors Jun 18
New major risk - Revenue and earnings growth Jun 17 See more updates
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Sep 14
Price target decreased by 20% to CA$0.40 Sep 13
Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024 Sep 09
Valeo Pharma Inc. Announces Board Changes Aug 07
Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors Jun 18
New major risk - Revenue and earnings growth Jun 17
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Jun 16
Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price Boost Jun 14
Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024 Jun 06
Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% Lower Apr 20
New major risk - Market cap size Apr 03
Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors Mar 22
First quarter 2024 earnings released Mar 15
New major risk - Revenue and earnings growth Mar 15
Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024 Mar 08
Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or Pricing Mar 02
Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024 Feb 27
Valeo Pharma Inc. Announces Board Changes Feb 13
Price target decreased by 12% to CA$0.72 Feb 05
Consensus revenue estimates fall by 14% Feb 05
Full year 2023 earnings: EPS and revenues miss analyst expectations Jan 30
Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024 Jan 23
Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price Jump Jan 17
New minor risk - Share price stability Jan 17
Valeo Pharma Inc. Announces Chief Financial Officer Changes Nov 21
Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of Directors Nov 08
New major risk - Market cap size Oct 31
New minor risk - Profitability Oct 16
Consensus EPS estimates fall by 23% Sep 20
Price target decreased by 16% to CA$1.23 Sep 16
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Sep 15
Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023 Sep 08 Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement Québec Sep 01
Consensus EPS estimates upgraded to CA$0.18 loss Jul 06
Less than half of directors are independent Jun 29
Valeo Pharma Inc. Announces Board Appointments Jun 23
Forecast breakeven date pushed back to 2025 Jun 17
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Jun 15
Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023 Jun 09
Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29% Jun 08
First quarter 2023 earnings: EPS misses analyst expectations Mar 17
Independent Director exercised options to buy CA$151k worth of stock. Mar 02
Valeo Pharma Obtains Public Reimbursement for Onstryv in Quebec Feb 08
Consensus EPS estimates fall by 31% Feb 06
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 01
Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 Patients Jan 27
Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023 Jan 26
Valeo Pharma Inc. Announces Stepping Down of Frederic Fasano as President and Chief Operating Officer Nov 22 Valeo Pharma Inc. Revises Revenue Guidance for the Fourth Quarter of 2022
Price target increased to CA$1.63 Nov 16
Less than half of directors are independent Nov 16
Valeo Pharma Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 Sep 16
Third quarter 2022 earnings: EPS misses analyst expectations Sep 14
Valeo Pharma Inc. to Report Q3, 2022 Results on Sep 13, 2022 Sep 10
Valeo Pharma Announces Executive Appointments Aug 31
Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24% Jun 24
Consensus revenue estimates fall by 24% Jun 21
Key Executive recently bought CA$113k worth of stock Jun 19
Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts Jun 17
No longer forecast to breakeven Jun 17
Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint Jun 15
Valeo Pharma Inc. to Report Q2, 2022 Results on Jun 14, 2022 Jun 09
Less than half of directors are independent May 01
Price target decreased to CA$1.70 Apr 27
Consensus EPS estimates fall by 42% Mar 31
Key Executive exercised options to buy CA$1.5m worth of stock. Mar 12
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 03
Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022 Feb 26
Valeo Pharma Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 22
Price target decreased to CA$1.77 Jan 12
Valeo Pharma's Hespercotm Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted for Publication Jan 06
Valeo Pharma Inc. announced that it expects to receive CAD 20 million in funding from Investissement Québec, Investment Arm and other investors Nov 25
Key Executive recently bought CA$90k worth of stock Oct 23
Key Executive recently bought CA$75k worth of stock Oct 08
Key Executive recently bought CA$78k worth of stock Oct 02
Third quarter 2021 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 3Q 2020) Sep 24
Senior VP & CFO recently bought CA$100k worth of stock Jul 18
Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™ Jul 15
Senior VP & CFO recently bought CA$200k worth of stock Jul 01
Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.015 loss in 2Q 2020) Jul 01
Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million. Jun 30
Valeo Pharma Inc. Announces Commercial Launch of Enerzair Breezhaler and Atectura Breezhaler Jun 23
Valeo Pharma Inc. Announces Outlook for Its Second Quarter Ended April 30, 2021 May 27
Valeo Pharma Inc. announced that it has received CAD 6.645 million in funding Apr 28
President recently bought CA$176k worth of stock Apr 23
Valeo Pharma Inc. announced that it expects to receive CAD 4 million in funding Apr 16
First quarter 2021 earnings released: CA$0.027 loss per share (vs CA$0.02 loss in 1Q 2020) Apr 03
Full year 2020 earnings released: CA$0.082 loss per share (vs CA$0.073 loss in FY 2019) Feb 27
Revenue misses expectations Feb 27
Valeo Pharma Inc., Annual General Meeting, Apr 28, 2021 Feb 26
New 90-day low: CA$0.99 Feb 26
Valeo Pharma Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 20
Valeo Pharma Inc. and Ingenew Pharma Inc. Announce HespercoTM Capsules Feb 18
Have Insiders Been Buying Valeo Pharma Inc. (CSE:VPH) Shares This Year? Feb 08 Shareholder Returns VPH CA Pharmaceuticals CA Market 7D 0% -0.8% -0.7% 1Y -67.9% -27.4% 16.3%
See full shareholder returns
Return vs Market: VPH underperformed the Canadian Market which returned 21.5% over the past year.
Price Volatility Is VPH's price volatile compared to industry and market? VPH volatility VPH Average Weekly Movement 19.9% Pharmaceuticals Industry Average Movement 12.0% Market Average Movement 8.1% 10% most volatile stocks in CA Market 17.4% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: VPH's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: VPH's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
Show more Valeo Pharma Inc. Fundamentals Summary How do Valeo Pharma's earnings and revenue compare to its market cap? VPH fundamental statistics Market cap CA$4.44m Earnings (TTM ) -CA$32.12m Revenue (TTM ) CA$53.38m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VPH income statement (TTM ) Revenue CA$53.38m Cost of Revenue CA$41.36m Gross Profit CA$12.02m Other Expenses CA$44.14m Earnings -CA$32.12m
Last Reported Earnings
Jul 31, 2024
Earnings per share (EPS) -0.33 Gross Margin 22.51% Net Profit Margin -60.18% Debt/Equity Ratio -110.1%
How did VPH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/13 13:28 End of Day Share Price 2024/10/01 00:00 Earnings 2024/07/31 Annual Earnings 2023/10/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Valeo Pharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Neil Linsdell iA Capital Markets Chelsea Stellick iA Capital Markets Scott McAuley Paradigm Capital, Inc.
Show 0 more analysts 
